The Radio Chipmaker Sitting at a Make-or-Break Price Level

This is one of those setups where sentiment has done most of the damage already.

The stock has been left behind, but the business still sits in critical parts of the connectivity stack.

If demand stabilizes and management executes, the upside can come faster than most people expect.

Act Now (Sponsored)

A Little-Known SpaceX Strategy Anyone Can Use

This is time-sensitive, so we’ll be direct.

For the first time, James Altucher is explaining how everyday investors can gain
pre-IPO exposure to SpaceX—starting with as little as $100.

That means there may be a way to position before Elon Musk’s next IPO event, rather than competing once Wall Street piles in.

What makes this especially interesting?

• No special accounts required

• Can be done inside a regular brokerage account

• Takes just minutes once you know what to buy

James reveals the name and ticker symbol in a short, free video—so you can decide for yourself if it makes sense.

Click here to watch the free video now

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Acadia Healthcare | ACHC

Price: $13.43

Acadia is the most damaged chart in today’s lineup, down roughly 68% over the past year.

At about $14, it is trading closer to its $11 low than to its $45 high, which tells you investors have priced in serious skepticism.

The valuation looks optically reasonable with a low teens P/E, but a low multiple is not a catalyst by itself.

What matters here is whether the business can rebuild trust with cleaner visibility and fewer surprises.

Behavioral health demand is not going away, but the market is clearly questioning execution, reimbursement dynamics, and how predictable the earnings stream really is. 

This is the kind of name that can rip higher if uncertainty fades, because the starting point is so depressed. But it can also stay trapped if investors continue treating it as headline risk.

Why it matters for you: ACHC is a sentiment reset story. The upside is big if the narrative stabilizes, but you need patience and strong risk control.

Alkermes | ALKS

Price: $33.91

Alkermes is the steadier operator of the group, up about 12% over the past year and trading near the upper end of its range.

With a mid teens P/E and a market cap around $5.6B, it reads more like a disciplined, cash-generating biotech than a moonshot.

That matters in a market where investors still punish anything that feels like endless R&D spending with unclear payoff.

The appeal is consistency and clear product economics. Investors tend to reward biotech names that can deliver repeatable earnings without requiring perfect market conditions. 

The risk is that biotech sentiment can still swing violently, even for better businesses, especially if broader risk appetite cools or if the market starts favoring faster growers again.

Still, Alkermes often trades like a relative safe harbor in its category.

Why it matters for you: ALKS offers a cleaner risk profile than most biotech. It may not be explosive, but it can act like a steadier compounder if execution stays tight.

Free Investor Access (Sponsored)

The New 5 Stocks Set to Double

A new research report highlights 5 stocks with the strongest potential to double in the year ahead.

Each was selected from thousands of companies and shows a rare mix of:

• Strong fundamentals

• Bullish technical setups

Past versions of this report delivered gains of +175%, +498%, and even +673%¹ — and the latest edition is free for a short time.

Available only until MIDNIGHT TONIGHT.

Download the free report

InMode | INMD

Price: $15.13

InMode is the classic value screen that keeps testing investor patience. The stock is down about 17% over the past year, trading near $14, and it carries a very low single-digit P/E.

That kind of valuation usually signals one of two things: the market expects earnings to shrink, or it does not trust the durability of the business. Sometimes it is both.

The bull case is simple. If demand for aesthetic procedures holds up and the company proves it can defend margins, the multiple does not need to stay this depressed. Even a modest re-rating can drive strong returns. 

The bear case is that competition, pricing pressure, or slower procedure volumes keep the market in skepticism mode.

InMode does not need hype, it needs proof that the business is not structurally weakening.

Why it matters for you: INMD is a low-expectations setup. If fundamentals stabilize, upside can be meaningful. If not, cheap can stay cheap.

Hims & Hers | HIMS

Price: $28.67

Hims & Hers looks like the market is still arguing with itself. Shares are down slightly over the past year, but the stock is far off the $73 high, sitting near $29.

At this level, investors are balancing a strong consumer brand and a powerful distribution model against concerns about valuation, competition, and how sustainable growth is as the category gets crowded.

The company sits at the intersection of telehealth, subscription commerce, and consumer wellness.

That mix can scale beautifully when customer acquisition stays efficient and retention holds. 

But the market also punishes any hint that growth is being bought at the expense of profitability.

This is a stock that can move sharply on a single quarter, for better or worse, because sentiment remains fragile.

Why it matters for you: HIMS is a growth stock that still needs to prove staying power. If it delivers clean growth with improving margins, it can re-rate. If growth wobbles, volatility comes fast.

Qorvo | QRVO

Price: $77.18

Qorvo enters 2026 in an awkward, but potentially interesting, spot. Shares are down about 8% over the past year and still well below the $106 area that marked the high.

At roughly $81, the market is treating Qorvo like a company stuck in a slow growth pocket, with limited excitement and little patience for any demand wobble.

The opportunity is that Qorvo is not a narrative stock, it is a plumbing stock. It sells critical radio frequency components that show up in smartphones and other connected devices.

When those cycles improve, these names can re-rate quickly because investors stop pricing them like melting ice cubes.

The risk is that the next upgrade cycle takes longer than hoped, or margin recovery proves slower than the market wants.

Why it matters for you: QRVO is a cyclical rebound candidate. If device demand improves and margins stabilize, the stock can snap back. If not, it can stay range-bound and frustrating.

 Stat of the Day: 24%

U.S. consumer prices have risen about 24% in total over the last five years, roughly 4.5% per year on average.

That matters because even if inflation prints look calmer lately, households are still living with the cumulative reset in the cost of everyday life.